Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseOsteomalacia, tumor-inducedSubgroupICD10M83.8-MeSHSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBurosumabSupportive substanceBurosumabSupportive substanceBurosumabSupportive substanceBurosumabNo. Substances1Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksConstipationHeadacheInfectionsMyalgiasRash only studiesPublicationAuthorJan de Beur SMDiseaseTumorinduzierte Osteomalazie durch erhöhten FGF23-Spiegel, gekennzeichnet durch renalen Phosphatverlust und Knochendemineralisation i.d.R aufgrund eines gemischt bindegewebigen phosphaturischen mesenchymalen TumorsOriginJohns Hopkins University School of Medicine, Baltimore, MD, USAProtocols in Revision 1 protocol foundProtocols under revision.Burosumab 0.3, Osteomalacia, tumor-induced (PID2057 V1.0)
